Key result
A review of 31 clinical trials supports the use of ACC-recommended pharmacological agents for heart failure, highlighting the need to overcome clinical inertia and optimize management.
Why the study?
Heart failure classifications and limited research on treatment outcomes in HFmrEF and HFpEF complicate pharmacological management, motivating a review of ACC pharmacotherapy guidelines and supporting trial evidence.
Population
31 studies on treatment for HFrEF, HFmrEF, and HFpEF
Comparison
ACC-recommended pharmacological agents vs current evidence from trials and registries
Design
Review
Authors
Loading...
Supports optimization of ACC-recommended HF therapies now; confirms benefits across 31 trials and targets inertia reduction.
This review summarizes current ACC pharmacotherapy guidelines for heart failure and emphasizes the need to overcome clinical inertia to optimize patient management.
Shubrook et al. (2024) conducted a review in Heart failure. Pharmacological agents for heart failure was evaluated. A review of 31 clinical trials supports the use of ACC-recommended pharmacological agents for heart failure, highlighting the need to overcome clinical inertia and optimize management.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: